BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

524636

OXYGENTAPH

img img img img
No Data Available

OXYGENTA PHARMACEUTICAL LIMITE Share Price Update

As of the latest trading session, OXYGENTA PHARMACEUTICAL LIMITE share price is currently at ₹ 60.01, which is up by ₹ 0.44 from its previous closing. Today, the stock has fluctuated between ₹ 59.63 and ₹ 62.53. Over the past year, OXYGENTA PHARMACEUTICAL LIMITE has achieved a return of -19.71 %. In the last month alone, the return has been 0.25 %. Read More...

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

OXYGENTA PHARMACEUTICAL LIMITE fundamentals


  • Market cap (Cr)

    [-]

  • P/E Ratio (TTM)

    [-]

  • Beta

    [-]

  • Book Value / share

    [-]

  • Return on equity

    [-]%

  • EPS (TTM)

    [-]

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    [-]

info icon alternate text
  • Market cap (Cr)

    220.50

  • P/E Ratio (TTM)

    -12.86

  • Beta

    0.97

  • Book Value / share

    -9.91

  • Return on equity

    0.00%

  • EPS (TTM)

    0.00

  • Dividend yield

    [-]%

  • Net profit/quarter (Cr)

    -4.93

info icon alternate text

OXYGENTA PHARMACEUTICAL LIMITE Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars SEP 2025 (Values in Cr)
Revenue 14.30
Operating Expense 20.68
Net Profit -4.93
Net Profit Margin (%) -34.47
Earnings Per Share (EPS) -1.33
EBITDA -4.63
Effective Tax Rate (%) 23.44
Particulars JUN 2025 (Values in Cr)
Revenue 15.13
Operating Expense 23.43
Net Profit -6.11
Net Profit Margin (%) -40.38
Earnings Per Share (EPS) -1.65
EBITDA -6.67
Effective Tax Rate (%) 25.03
Particulars MAR 2025 (Values in Cr)
Revenue 49.47
Operating Expense 53.05
Net Profit -2.15
Net Profit Margin (%) -4.34
Earnings Per Share (EPS) -0.60
EBITDA -1.90
Effective Tax Rate (%) 43.42
Particulars DEC 2024 (Values in Cr)
Revenue 33.21
Operating Expense 38.66
Net Profit -3.93
Net Profit Margin (%) -11.83
Earnings Per Share (EPS) 1.07
EBITDA -3.86
Effective Tax Rate (%) 20.76
Particulars SEP 2024 (Values in Cr)
Revenue 14.01
Operating Expense 17.53
Net Profit -2.85
Net Profit Margin (%) -20.34
Earnings Per Share (EPS) -0.81
EBITDA -1.42
Effective Tax Rate (%) -2.88
Particulars MAR 2025 (Values in Cr)
Revenue 109.30
Operating Expense 124.69
Net Profit -10.30
Net Profit Margin (%) -9.42
Earnings Per Share (EPS) -2.86
EBITDA -8.96
Effective Tax Rate (%) 28.22
Particulars MAR 2024 (Values in Cr)
Revenue 39.64
Operating Expense 53.59
Net Profit -3.48
Net Profit Margin (%) -8.77
Earnings Per Share (EPS) -1.09
EBITDA -9.62
Effective Tax Rate (%) 74.90
Particulars MAR 2023 (Values in Cr)
Revenue 30.99
Operating Expense 41.65
Net Profit -11.57
Net Profit Margin (%) -37.33
Earnings Per Share (EPS) -6.36
EBITDA -7.82
Effective Tax Rate (%) -1.75
Particulars MAR 2022 (Values in Cr)
Revenue 60.52
Operating Expense 61.56
Net Profit -0.61
Net Profit Margin (%) -1.00
Earnings Per Share (EPS) -0.48
EBITDA 2.02
Effective Tax Rate (%) -24.48
Particulars MAR 2021 (Values in Cr)
Revenue 52.03
Operating Expense 51.18
Net Profit 2.93
Net Profit Margin (%) 5.63
Earnings Per Share (EPS) 2.87
EBITDA 6.11
Effective Tax Rate (%) 6.38
Particulars MAR 2025 (Values in Cr)
Book Value / Share -6.77
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -7.97
Particulars MAR 2024 (Values in Cr)
Book Value / Share -6.18
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -24.27
Particulars MAR 2023 (Values in Cr)
Book Value / Share -32.53
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -25.27
Particulars MAR 2022 (Values in Cr)
Book Value / Share -24.38
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 2.43
Particulars MAR 2021 (Values in Cr)
Book Value / Share -37.27
ROE % -5.79
ROCE % 7.89
Total Debt to Total Equity 0.00
EBITDA Margin 7.55
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 0.12
Total Assets 83.42
Total Liabilities 83.42
Total Equity -25.02
Share Outstanding 36983500
Price to Book Ratio -11.75
Return on Assets (%) -11.60
Return on Capital (%) -26.02
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 63.19
Total Liabilities 63.19
Total Equity -20.12
Share Outstanding 33483500
Price to Book Ratio -4.69
Return on Assets (%) -5.50
Return on Capital (%) -9.38
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.10
Total Assets 54.26
Total Liabilities 54.26
Total Equity -46.20
Share Outstanding 14201300
Price to Book Ratio -1.13
Return on Assets (%) -21.32
Return on Capital (%) -53.09
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.15
Total Assets 31.17
Total Liabilities 31.17
Total Equity -34.62
Share Outstanding 14201300
Price to Book Ratio -0.99
Return on Assets (%) -1.95
Return on Capital (%) -3.49
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.44
Total Assets 33.86
Total Liabilities 33.86
Total Equity -38.01
Share Outstanding 10201300
Price to Book Ratio 0.00
Return on Assets (%) 8.65
Return on Capital (%) 29.69
Particulars MAR 2025 (Values in Cr)
Net Income -11.55
Cash from Operations 2.76
Cash from Investing -11.24
Cash from Financing 8.66
Net change in Cash 0.02
Free Cash Flow 14.15
Particulars MAR 2024 (Values in Cr)
Net Income -13.87
Cash from Operations -13.04
Cash from Investing -4.08
Cash from Financing 17.13
Net change in Cash 0.00
Free Cash Flow -8.94
Particulars MAR 2023 (Values in Cr)
Net Income -11.37
Cash from Operations -1.63
Cash from Investing -9.63
Cash from Financing 11.22
Net change in Cash -0.04
Free Cash Flow 8.01
Particulars MAR 2022 (Values in Cr)
Net Income -0.48
Cash from Operations -1.55
Cash from Investing -4.94
Cash from Financing 6.33
Net change in Cash -0.28
Free Cash Flow 3.38
Particulars MAR 2021 (Values in Cr)
Net Income 3.14
Cash from Operations -1.40
Cash from Investing -6.71
Cash from Financing 8.66
Net change in Cash 0.32
Free Cash Flow 5.33
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 29.08 14.25 1.51 222.85 28.35 / 68.00
BLISS GVS PHARMA LTD 169.55 16.35 1.58 1792.53 105.05 / 190.65
CIPLA LTD 1503.90 22.33 3.69 121480.71 1310.05 / 1672.20
FERMENTA BIOTECH LIMITED 274.50 7.21 2.06 807.88 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2474.85 43.98 24.55 41925.45 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 29.08 23.64 4.05 222.85 28.35 / 68.00
AMRUTAJAN HEALTH LTD 689.45 35.16 5.82 1993.24 548.05 / 829.00
ASTRAZENECA PHARMA IND LT 9055.55 97.93 28.33 22638.88 6301.00 / 10653.05
BLISS GVS PHARMA LTD 169.55 22.88 1.62 1792.53 105.05 / 190.65

OXYGENTA PHARMACEUTICAL LIMITE shareholding pattern

Holding

42.02%
57.95%
0.02%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

Transparent Pricing and 360° Services

Choose a Plan That Suits Your Goals and Needs

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Stock Picks by Research Analysts tick Seamless Onboarding

Subscription Charge : ₹2,500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% on Delivery 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Stock Picks by Research Analysts tick Experienced Dealer Support

OXYGENTA PHARMACEUTICAL LIMITE Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
59.63 0.11 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 60.20
  • 26 Days 62.60
  • 10 Days 61.00
  • 50 Days 66.80
  • 12 Days 61.20
  • 100 Days 74.60
  • 20 Days 62.00
  • 200 Days 78.20
59.59 PIVOT

First Support

58.17

First Resistance

60.97

Second Support

56.79

Second Resistance

62.39

Third Support

55.37

Third Resistance

63.77

RSI

41.17

ADX

11.77

MACD

-1.46

Williams % R

-85.66

Commodity Channel Index (CCI)

-126.90

Date

2025-11-24

Week

49815.00

Same Day

66116.00

Month

19404.00

1 Year

0.98

3 Year

0.51

Over 1 Month

0.25%

down

Over 1 Year

-19.71%

down

Over 3 Months

-26.42%

down

Over 3 Years

32.50%

down

Over 6 Months

-33.43%

down

Over 5 Years

44.14%

down

OXYGENTA PHARMACEUTICAL LIMITE Corporate Actions

OXYGENTA PHARMACEUTICAL LIMITE Share Price

Oxygenta Pharmaceutical Limited (Formerly known S S Organics Ltd) was incorporated as Private Limited Company in year 1990 and converted into a Limited Company in 1993, with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. Later, the Company changed its name from S.S. Organics Ltd. to Oxygenta Pharmaceutical Limited in 2021-22.

The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs. The Company is doing contract manufacturing work for APL and also having its own production. The Company is engaged in manufacture of bulk drugs. It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs. The Company has plant located at Medak in Andhra Pradesh.

The Company has been doing contract manufacturing work with APL for manufacturing of Cirprofloxacin HCL from Q-Acid and has been manufacturing Pantaprozole Sodium and Gabapentine for own production. To minimize the working capital requirement and to have consistent income, it is necessary to continue contract manufacturing work till the Company gets working capital limits from any Bank. This contract manufacturing helps it to meet major operational expenses of the Company. Since the Company started commercial production in July, 2015 after fire accident, it is in the process of stabilizing the manufacturing and marketing.

Parent organization Indian Private
NSE symbol [-]
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Oxygenta Pharmaceutical Ltd?

Answer Field

Oxygenta Pharmaceutical Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 59.63 as on Nov 25 2025 03:09 PM.

What is the Market Cap of Oxygenta Pharmaceutical Ltd Share?

Answer Field

The market cap of Oxygenta Pharmaceutical Ltd for NSE ₹ 0.00 & for BSE ₹ 220.50 as on Nov 25 2025 03:09 PM.

What is the 52 Week High and Low of Oxygenta Pharmaceutical Ltd?

Answer Field

The 52 Week High and Low of Oxygenta Pharmaceutical Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 133.50 and ₹ 53.56.

What is 1 year return for Oxygenta Pharmaceutical Ltd?

Answer Field

The 1 year returns on the stock has been -19.71%.

What is the P/E Ratio of Oxygenta Pharmaceutical Ltd Share?

Answer Field

As on Nov 25 2025 03:09 PM the price-to-earnings (PE) ratio for Oxygenta Pharmaceutical Ltd share is -12.86.

What is the PB ratio of Oxygenta Pharmaceutical Ltd Share?

Answer Field

As on Nov 25 2025 03:09 PM, the price-to-book (PB) ratio for Oxygenta Pharmaceutical Ltd share is -9.91.

How to Buy Oxygenta Pharmaceutical Ltd Share?

Answer Field

You can trade in Oxygenta Pharmaceutical Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Oxygenta Pharmaceutical Ltd Share on Bajaj Broking App?

Answer Field

To buy Oxygenta Pharmaceutical Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Oxygenta Pharmaceutical Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59